Gauchers

Gaucher Disease Type III Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Gaucher Disease Type III Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Gaucher Disease Type III pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type III, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary d...

$2,000.00

Gaucher Disease Type I Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Gaucher Disease Type I Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Gaucher Disease Type I pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type I, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databas...

$2,000.00

Gaucher Disease Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Gaucher Disease Type II Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Gaucher Disease Type II pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gaucher Disease Type II, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary data...

$2,000.00

Gaucher’s Disease - Pipeline Insight, 2021

Fri, 19 Mar 2021 14:59:26 +0000

DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Gaucher’s Disease Understanding Gaucher’s Disease: Overview Gaucher disease is a rare, inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain fats (lipids), specifically the glycolipid glucocerebroside, throughout the body especially within the bone marrow, spleen and liver. The symptoms and physical findings associated with Gaucher disease vary greatly from patient to patient. Gaucher disease is categorized as a lysosomal storage disorder (LSD). Lysosomes are the major digestive units in cells. Enzy...

$1,500.00

Global Gaucher Disease Market Research Report 2018

Fri, 07 Dec 2018 10:39:03 +0000

Gaucher Disease Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). The report firstly introduced the Gaucher Disease basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis. The report includes six parts, dealing with: 1.) Basic Information; 2.) Asia Gaucher Disease Market; 3.) North American Gaucher Disease Market; 4.) European Gaucher Disease Market; 5.) Market Entry and Investment Feas...

$2,850.00

Gaucher Disease - Pipeline Review, H2 2017

Thu, 18 Jan 2018 15:45:29 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease - Pipeline Review, H2 2017, provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape.

Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gaucher Disease ...

$2,000.00

Gaucher Disease - Pipeline Review, H2 2016

Fri, 07 Apr 2017 13:51:23 +0000

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Gaucher Disease Overview 8
Therapeutics Development 9
Pipeline Products for Gaucher Disease - Overview 9
Pipeline Products for Gaucher Disease - Comparative Analysis 10
Gaucher Disease - Therapeutics under Development by Companies 11
Gaucher Disease - Therapeutics under Investigation by Universities/Institutes 12
Gaucher Disease - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Gaucher Disease - Products under Development by Companies 15
Gaucher Disease - Products under Investigation by Universities/Institutes 16
Gaucher Disease - Companies Involved in Therapeutics Development 17
Actelion Ltd 17
Genzyme Corp 18
greenovation Biotech GmbH 19
JCR Pharmaceuticals Co Ltd 20
Lixte Biotechnology Holdings Inc 21
Lysosomal Therapeutics Inc 22
Neuraltus Pharmaceuticals Inc 23
Pharming Group NV 24
Protalix BioTherapeutics Inc 25
Sangamo BioSciences ...

$2,000.00

Gaucher Disease Type III - Pipeline Review, H2 2016

Fri, 07 Apr 2017 13:51:23 +0000

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gaucher Disease Type III Overview 6
Therapeutics Development 7
Pipeline Products for Gaucher Disease Type III - Overview 7
Gaucher Disease Type III - Therapeutics under Development by Companies 8
Gaucher Disease Type III - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Gaucher Disease Type III - Products under Development by Companies 11
Gaucher Disease Type III - Companies Involved in Therapeutics Development 12
Actelion Ltd 12
Belrose Pharma Inc 13
Erad Therapeutics Inc 14
Genzyme Corp 15
Shire Plc 16
Gaucher Disease Type III - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
ambroxol - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26 $2,000.00

Gaucher Disease (GD)- Market Insights, Epidemiology and Market Forecast-2023

Wed, 24 Aug 2016 13:19:26 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Gaucher Disease (GD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Gaucher Disease (GD) forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Gaucher Disease (GD) till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Gaucher Disease (GD) market. • Identifying patient populations in the global “Gaucher Disease (GD)market to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Gaucher Disease (GD) therapeutics in each of the market...

$4,950.00

Gaucher Disease Global Clinical Trials Review, H1, 2016

Tue, 07 Jun 2016 09:32:09 +0000

Summary

GlobalData's clinical trial report, “Gaucher Disease Global Clinical Trials Review, H1, 2016" provides an overview of Gaucher Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Gaucher Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive...

$2,500.00